The Canadian Association for Population Therapeutics presents:

“Healthcare Cost, Quality, and Policy: Driving Stakeholder Innovation in Process and Practice”

PROGRAM

November 17th - 19th, 2013
Toronto, Ontario
Metropolitan Hotel Toronto
(after November 13, 2013, the hotel will be known as the DoubleTree by Hilton)
108 Chestnut Street
Toronto, Ontario
CAPT MISSION & VISION
The CAPT Mission is to advance population-based research of therapeutic interventions to improve the health outcomes of Canadians by:

- Bringing together diverse perspectives
- Facilitating open exchange of ideas and collaboration, and
- Influencing policy and practice

The CAPT Vision is to become the recognized Canadian leader for linking population-based therapeutic research, policy and practice to optimize health outcomes.
CAPT 2013 BOARD OF DIRECTORS:
Nicole Mittmann – CAPT President, HOPE Research Centre, Sunnybrook Health Sciences Centre, University of Toronto
Anick Bérard – CAPT Past President, University of Montréal
Allan Gillman – CAPT President Elect, IMS Brogan
Suzanne Cadarette, University of Toronto
Brian Chan (student member), University of Toronto
Dean Eurich, University of Alberta
Kirsten Garces, AMGEN Canada
Naeem Ladhani, Alberta Health Services
Suzanne Lepage, Suzanne Lepage Consulting
Colleen Metge, Winnipeg Regional Health Authority
Laura Park-Wyllie, Ontario Health Technology Advisory Committee Health Quality Ontario
Louise Perrault, International Market Access Consulting
Valencia Remple, Pfizer Canada Inc.
Melissa Thompson, Cornerstone Research Group

CAPT 2013 SCIENTIFIC PROGRAM COMMITTEE:
Allan Gillman, IMS Brogan
Louise Perrault, International Market Access Consulting
Laura Park-Wyllie, Ontario Health Technology Advisory Committee Health Quality Ontario
Dean Eurich, University of Alberta
Valencia Remple, Pfizer Canada Inc.

CAPT 2013 LOCAL ORGANIZING COMMITTEE:
Nicole Mittmann, HOPE Research Centre, Sunnybrook Health Sciences Centre
Suzanne Lepage, Suzanne Lepage Consulting
Kirsten Garces, AMGEN Canada
Suzanne Cadarette, University of Toronto
Brian Chan, University of Toronto
Peggy Kee, HOPE Research Centre, Sunnybrook Health Sciences Centre

CAPT 2013 PARTNERSHIP COMMITTEE:
Angel Rocchi, Axia Research
Melissa Thompson, Cornerstone Research Group
Laurene Redding, Takeda Inc.
Nigel Rawson, Eastlake Research Group

CAPT 2013 MEMBERSHIP COMMITTEE:
Valencia Remple, Pfizer Canada Inc.
Naeem Ladhani, Alberta Health Services

www.capt-actp.com
“Healthcare Cost, Quality, and Policy: Driving Stakeholder Innovation in Process and Practice”

Message from the President

Nicole Mittmann
CAPT President

CAPT 2013 Conference Overview
“Healthcare Cost, Quality, and Policy: Driving Stakeholder Innovation in Process and Practice”

Sunday, November 17, 2013

Partner of the Day: AstraZeneca Canada

07:15 - 17:00  Registration
  Location: Mandarin Ballroom Foyer

Pre-Conference Activities

Pharmaceutical Value Framework Workshop (CAPT Associated Session)-Phase I
  Location: Mandarin Ballroom Foyer
  08:30 - 12:00  Value of Medicines - First Phase - Invited Session
                 Craig Mitton – Facilitator, Centre for Clinical Epidemiology and Evaluation and
                 University of British Columbia
                 N.B. Attendance is limited for this phase

Network Meta Analysis Symposium
  Location: Mandarin Ballroom Foyer
  09:00 - 09:50  Introduction to Network Meta Analysis
  09:50 - 10:30  Checklist to Review Network Meta Analysis
  10:30 - 12:00  Case Study
                 Melissa Thompson et al, Cornerstone Research Group
                 George Wells, Canadian Collaboration for Drug Safety, Effectiveness & Network
                 Meta Analysis
“Healthcare Cost, Quality, and Policy: Driving Stakeholder Innovation in Process and Practice”

Sunday, November 17, 2013

Partner of the Day: AstraZeneca Canada

07:15 - 17:00  **Registration**
Location: Mandarin Ballroom Foyer

---

**Conference Commencement**
Location: Mandarin Ballroom

13:00 - 13:10  **Welcome Introduction to the Conference**
Nicole Mittmann, HOPE Research Centre, Sunnybrook Health Sciences Centre and President, CAPT

13:10 - 13:50  **Measuring What Matters in Health Care: Cost vs. Value**
Chair: Nicole Mittmann
Speaker: Anne Snowdon, Chair, International Centre for Health Innovation, Richard Ivey School of Business, Western University

13:50 - 14:30  **Healthy Debate Initiative**
Chair: Allan Gillman
Speaker: Andreas Laupacis, Keenan Research Centre, Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto

14:30 - 15:00  **Break**

15:00 - 15:40  **Value of Medicines - Report to CAPT Members - Sponsored by: Merck**
Chair: Nicole Mittmann
Speaker: Craig Mitton, Centre for Clinical Epidemiology and Evaluation, University of British Columbia

15:40 - 16:10  **HTA, Value-based Decision Making, and Innovation**
Chair: Nicole Mittmann
Speaker: Chris Henshall, University of York, United Kingdom
16:10 - 17:10  Contributed Oral Presentations
Chair: Colleen Metge

Psychotropic medication use and 10-year incident fracture risk in men and women ages 50 and older in the population-based Canadian Multicentre Osteoporosis Study (CaMoS).
Cristiano Moura

The impact of recent generic drug price policies on pharmaceutical innovation: A theoretical rationale and proposal of a method supporting innovation in areas of unmet medical need.
Pierre-Alexandre Dionne

A qualitative assessment of patients’ beliefs about adherence to oral anti-diabetes drug treatment.
Line Guénette

Current management and associated cost of Metastatic castration-resistant prostate cancer in Canada.
Alice Dragomir

17:10 - 17:20  Day 1 Summary Comments
Nicole Mittmann, HOPE Research Centre, Sunnybrook Health Sciences Centre and President, CAPT

17:20 - 18:20  Reception & Contributed Poster Presentations #1
Location: Mezzanine

17:20 - 20:00  Student Mentoring/ Student Social Event (open to CAPT Student Registrants only)
Location: Mandarin Ballroom

Monday, November 18, 2013

Partner of the Day: Hoffman-LaRoche Canada

07:00 - 17:00  Registration
Location: Mandarin Ballroom Foyer

08:00 - 08:50  Breakfast
Location: Mandarin Ballroom Foyer
08:50 - 09:00  
**Day Two Welcome**  
Location: Mandarin Ballroom  
Nicole Mittmann, HOPE Research Centre, Sunnybrook Health Sciences Centre and President, CAPT

09:00 - 09:50  
**The Future Shape of Healthcare in Canada**  
Location: Mandarin Ballroom  
Chair: Allan Gillman  
Speaker: Tom Brogan, Independent Consultant, former VP Global Oncology, IMS (retired)

9:50-10:20  
**Break**

10:20 - 12:00  
**The pan-Canadian Oncology Drug Review: Perspectives, Innovation, Policy**  
Location: Mandarin Ballroom  
Moderator: Jeffrey Hoch, Cancer Care Ontario and St. Michael’s Hospital  
- Mona Sabharwal, Executive Director, pCODR  
- Allan Grill, Chair, Committee to Evaluate Drugs at Ministry of Health and Long Term Care and pERC Family Practice Representative  
- Carole McMahon, pERC Patient Representative  
- Farzad Ali, Director, Health Economics Outcomes Research, Pfizer Canada  
- Kelvin Chan, Medical Oncologist, Sunnybrook Odette Cancer Centre

12:00 - 13:30  
**Lunch / CAPT Annual General Meeting (Lunch Sponsored by: Astellas)**  
Location: Mandarin Ballroom Foyer

13:30 - 14:50  
**Let’s get Real with Real World Data - Panel - sponsored by: Pfizer**  
Location: Mandarin Ballroom  
Moderator: Nigel Rawson, Eastlake Research Group  
- Steve Long, Director, National Public Policy, Shoppers Drug Mart  
- Marc Berger, Vice President, Real World Data and Analytics, Pfizer  
- David Henry, Professor, Health Systems Data, University of Toronto and Senior Scientist, Institute for Clinical Evaluative Sciences  
- Neil Corner, Director, Innovative Solutions, IMS Brogan

14:50 - 15:20  
**Break**
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Location</th>
<th>Chair</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:20 - 16:10</td>
<td>The Canadian Longitudinal Study on Aging</td>
<td></td>
<td>Laura Park-Wyllie</td>
<td>Parminder Raina, Lead Principal Investigator, CLSA/ELCV</td>
</tr>
<tr>
<td>16:10 - 17:10</td>
<td>Contributed Oral Presentations</td>
<td></td>
<td>Kirsten Garces</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Glucocorticoid-induced osteoporosis management among seniors.</td>
<td></td>
<td>Jordon Albaum</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Time series methods applied in drug utilization research: A systematic review.</td>
<td></td>
<td>Racquel Jandoc</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Methods for survival extrapolation within cost-effectiveness analyses that address concerns raised in pCODR reviews.</td>
<td></td>
<td>Daniel Grima</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Use of product listing agreements by Canadian provincial drug benefit plans.</td>
<td></td>
<td>Steve Morgan</td>
<td></td>
</tr>
<tr>
<td>17:10 - 17:20</td>
<td>Day 2 Summary Comments</td>
<td></td>
<td>Nicole Mittmann, HOPE Research Centre, Sunnybrook Health Sciences Centre and President, CAPT</td>
<td></td>
</tr>
<tr>
<td>17:20 - 18:20</td>
<td>Contributed Poster Presentations #2</td>
<td></td>
<td>Mezzanine Level</td>
<td></td>
</tr>
</tbody>
</table>
Tuesday, November 19, 2013

Partner of the Day: Novartis Canada

07:30 - 13:00  Registration

08:00 - 08:50  Breakfast
Location: Mandarin Ballroom Foyer

08:50 - 09:00  Day Three Welcome
Location: Mandarin Ballroom
Nicole Mittmann, HOPE Research Centre, Sunnybrook Health Sciences Centre
and President, CAPT

9:00 - 10:30  Opportunities and Challenges in the Private Payer Environment
Location: Mandarin Ballroom
Chair: Suzanne Lepage

Setting the Stage for Private Payers
Speaker: Ben Harrison, Manager, Group Strategic Relationships, Great West Life

Private Payer Stakeholders Panel Discussion
Moderator: Suzanne Lepage, Suzanne Lepage Consulting
  • Dean Eurich, University of Alberta
  • Ben Harrison, Manager, Group Strategic Relationships, Great West Life
  • Kathy Sotirakos, Chair - Rx&D's Private Payer Subcommittee, AMGEN Canada
  • Michael Swartz, Canadian Diabetes Association Board and National Advocacy Council member

10:30-11:00  Break

11:00 - 12:20  Understanding CIHR-DSEN Processes Using Case Examples;
From Signal to Study: how different parts of DSEN work together (CCNMA & CNODES); Methods for Designing Prospective Longitudinal Studies (CAN-AIM);
Real Applications and Lessons Learned in Knowledge Translation
Location: Mandarin Ballroom
Chair: Frances Hall
  • Robert Peterson – Moderator, DSEN Executive Director
  • George Wells - Canadian Collaboration for Drug Safety, Effectiveness & Network Meta-Analysis (CCNMA)
o Sasha Bernatsky – Canadian Network for Advanced Interdisciplinary Methods (CAN-AIM)
o David Henry – Professor, Health Systems Data, University of Toronto and Senior Scientist, Institute for Clinical Evaluative Sciences

12:20 - 13:20 Lunch (Sponsored by: IMS Brogan)

13:20 - 14:20 Contributed Oral Presentations - Concurrent Sessions

**Concurrent Session 1**
Location: Mandarin Ballroom A
Chair: Naeem Ladhani

**Development and validation of severity criteria for drug-related problems in chronic kidney disease patients.**
Patricia Quintana Bárquena

**Population-level Costs and Resource Utilization of Homecare for Persons with Alzheimer's Disease**
Nicole Mittmann

**Appraisal of non-inferiority margins in assessing study quality: New oral anticoagulants as an example.**
Samer Nuwwareh

**Safety and effectiveness of dabigatran versus warfarin in economic evaluations: A systematic review.**
Jathishnie Jegathisawaran

**Concurrent Session 2**
Location: Mandarin Ballroom B
Chair: Brian Chan

**Comparative Gastrointestinal Safety of Bisphosphonates: A Network Meta-analysis.**
Mina Tadrous

**Cost effectiveness of a systematic guidelines-based approach to the prevention and management of vascular disease in a primary care setting.**
Laveena Kamboj
Hospitalization for hemorrhage among warfarin recipients prescribed amiodarone.
Jason Lam

Creation of a reference set of the health preference values in oncology: A pilot study using an electronic data collection system.
Soo Jin Seung,

14:20 - 14:50  Break

14:50 - 15:40  Indirect treatment comparisons within the reimbursement process - Sponsored by: Janssen
Location: Mandarin Ballroom
Moderator: Jeffrey Hoch, Cancer Care Ontario and St Michael's Hospital
  o Doug Coyle - Epidemiology and Community Medicine, U of Ottawa
  o Karen Lee - Director, Health Economics, CADTH
  o Kristian Thorlund - Department of Clinical Epidemiology & Biostatistics, McMaster University

15:40 - 16:30  Pharmacy and Outcomes
Location: Mandarin Ballroom
Chair: Suzanne Cadarette
      Steve Long, Director, National Public Policy, Shoppers Drug Mart

16:30 - 17:00  CAPT Awards Ceremony / Conference Close
Allan Gillman, CAPT President Elect

For any inquiries: (abstracts, hotel, registration, etc.) please contact Ms. Peggy Kee (peggy.kee@sunnybrook.ca) or visit the CAPT website (www.capt-actp.com).
**Student Mentors**
Suzanne Cadarette
Brian Chan
Dean Eurich
Kirsten Garces
Frances Hall
Naeem Ladhani
Colleen Metge
Valencia Remple
Angela Rocchi
Melissa Thompson

**Judges-Oral Presentations**
Naeem Ladhani

**Judges-Poster Presentations**
Suzanne Cadarette
Kirsten Garces
Colleen Metge
Valencia Remple
ORAL PRESENTATIONS

(Note: Presenting Authors are underlined)


2 Dionne P-A, Ali F, Grobler M. The impact of recent generic drug price policies on pharmaceutical innovation: A theoretical rationale and proposal of a method supporting innovation in areas of unmet medical need.


4 Albaum JM, Lévesque LE, Liu YY, Cadarette SM. Glucocorticoid-induced osteoporosis management among seniors.

5 Jandoc R, Burden AM, Mamdani M, Cadarette SM. Time series methods applied in drug utilization research: A systematic review.

6 Grima DT, Brown S. Methods for survival extrapolation within cost-effectiveness analyses that address concerns raised in pCODR reviews.

7 Morgan SG, Friesen MK, Thomson PA, Daw JR. Use of product listing agreements by Canadian provincial drug benefit plans.


10
Jobin Gervais K, Sheehy O, Karam F, Bérard A. **Can we rely on pharmacy claims databases to ascertain maternal use of medications during pregnancy?**

11
Nuwwareh S, Richter T. **Appraisal of non-inferiority margins in assessing study quality: New oral anticoagulants as an example.**

12
Jegathisawaran J, Bowen JM, Khondoker F, Campbell K, Burke N, Goeree R, Holbrook A. **Safety and effectiveness of dabigatran versus warfarin in economic evaluations: A systematic review.**

13
Tadrous M, Wong L, Juurlink DN, Krahn M, Lévesque L, Mamdani M, Cadarette SM. **Comparative Gastrointestinal Safety of Bisphosphonates: A Network Meta-analysis.**

14
Kamboj L, Oh P, Kammila S, Casey W, Harterre D. **Cost effectiveness of a systematic guidelines-based approach to the prevention and management of vascular disease in a primary care setting.**

15
Lam J, Gomes T, Juurlink DN, Mamdani MM, Pullenayegum EM, Kearon C, Spencer FA, Paterson M, Zheng H, Holbrook AM. **Hospitalization for hemorrhage among warfarin recipients prescribed amiodarone.**

---

**POSTER PRESENTATIONS**

(Note: Presenting Authors are underlined)

16
Chan BC, Mittmann N, Krahn MD. **Systematic review of cost-of-illness studies in chronic ulcer population.**

17
Chan BC, Krahn MD, Mittmann N. **The health care resource utilization of recently spinal cord injured: Preliminary results.**

18
19
Samjoo IA, Grima DT. Consistencies in cancer therapy reimbursement recommendations made in Canada, Australia, Sweden, and United Kingdom.

20
Longo CJ. Cost-sharing for health care services: An examination of pharmaceutical reimbursement policies in Ontario.

21

22

23

24

25

26
Muanda FT, Bérard A. Antimalarial drug use during pregnancy and the risk of low birth weight (LBW): A systematic review.

27

28
Farahani P. Estimation of outpatient versus inpatient adverse drug reactions (ADRs) reporting using Ecology of Medical Care data.

30 Sirois C, Gagnon ME, Faubert M, Gascon H. Use of medication among young people with intellectual disability in Quebec.


33 Brown ST, Sauriol L. Cost-effectiveness of insulin glargine versus sitagliptin in insulin naïve patients with type 2 diabetes mellitus.


35 Woo V, Abbaszadeh B, Tahami Monfared AA, Leblond F, Stewart J. Targeting postprandial glucose (PPG) with the addition of a rapid acting meal time insulin is more efficient to lower A1C after 12 weeks than optimization of basal Insulin in patients with type 2 diabetes (T2D).

36 Woo V, Abbaszadeh B, Tahami Monfared AA, Leblond F, Stewart J. Targeting breakfast for type 2 diabetes (T2D) therapy appears more likely to succeed based on a subanalysis of START and INSIGHT Studies.

37 Xu Y, Holbrook AM, Simpson CS, Dowlatshahi D, Johnson AP. Prescribing pattern of novel oral anticoagulants following regulatory approval for atrial fibrillation in Ontario, Canada.


40  Gillman A. Using anonymized longitudinal patient data to monitor the impact of reimbursement policies on patient compliance.


42  Burden AM, Patterson JM, Gruneir A, Cadarette S. Potential impact of days supply errors in pharmacy data on measurement of compliance with osteoporosis medications.

43  Aoki A, Nguyen T, Abdallah M, Po P. The benefit of an automated step therapy program to manage diabetes medication use.


45  Cheng J, Castren M, Brommels M, Rose K, Mittmann N. Cost-Effectiveness of a physician-nurse supplementary triage assistance team (M DRNSTAT) in an Ontario academic emergency department.

46  Black CM, Tadrous M, Cadarette SM. Diffusion of methodological innovation in pharmacoepidemiology: High-dimensional propensity score co-authorship network analysis

47  De Cock E, Tao S, Desrosiers M-P, Millar D, Califaretti N. Time savings with trastuzumab subcutaneous (sc) injection vs. trastuzumab intravenous (iv) infusion: A time and motion study in 5 Canadian centres.

49
Grima DT, Samjoo IA. Lessons learned from the dedicated oncology drug review process in Canada: 2013 update.

50

51

52

53
Lam J, Schulman S, Witt DM, Vandvik PO, Qayyum F, Holbrook A. Anticoagulation control with daily low dose vitamin K to reduce clinically adverse outcomes and INR variability: A systematic review and meta-analysis.

54

55

56
Ma J, Polk G, Semelman S, Ling N. Impact of mandatory generic substitution policies on Canadian private payer drug plan costs and patients.

57
Desrosiers M-P, Lordan N, Reynolds MR, Robinson Jr DW, Payne KA. Using retrospective chart review methodology to characterize patients, treatment patterns and resource utilization in a cohort of patients with multicentric Castleman’s disease.
58
McCarron CE, Cao JQ, Ernst DS, Zaric GS. Costs and survival of patients with metastatic melanoma: Evidence from the Ontario Cancer Registry and administrative databases.

59

60
Snowdon AW, Pisterzi LF, Comrie R, Mittmann N. Exploring homecare services for persons with Alzheimer’s disease.

61
Stein D, Bassel M, Payne KA. Drug utilization and safety evaluations: Lessons learned from multinational retrospective chart review case studies.

62
2013 CAPT-ACTP
CONFERENCE PARTNERS

DIAMOND
Pfizer Canada Inc.

PLATINUM
AstraZeneca
DSEN / CNODES / CIHR
Hoffman-La Roche
Janssen
Merck Canada
Novartis Pharmaceuticals

GOLD
AMGEN Canada Inc.
Astellas Pharma Canada
Boehringer-Ingelheim Canada
Canada’s Research-Based Pharmaceutical Companies Rx&D
IMS Brogan
Nova Nordisk Canada
Takeda Canada Inc.

SILVER
Axia Research Inc.
Cornerstone Research
Eisai Limited
Gilead Sciences Canada Inc.
GlaxoSmithKline Inc.
InterMune Canada Inc.
Mapol Inc.
OptumInsight Life Sciences
Oxford Outcomes
Purdue Pharma

BRONZE
Axone Market Access Consulting Inc.
HOPE Research Centre
Institute of Health Economics